LEXINGTON, Mass., Sept. 17, 2018 /PRNewswire/ -- Pulmatrix,
Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company
developing innovative inhaled therapies to address serious
pulmonary diseases will present preclinical data on the
anti-inflammatory activity of PUR1800 (RV1162) at the ERS
International Congress 2018 in Paris,
France.
Aidan Curran, PhD and Senior
Director, Research at Pulmatrix Inc will present preclinical data
in an abstract entitled "PUR1800 (RV1162), a novel narrow spectrum
kinase Inhibitor, but not fluticasone, reduces TNFα-induced
cytokine release by primary bronchial epithelial cells from healthy
volunteers and COPD patients" at 8:30AM on Wednesday, September 19.
"This data supports the anti-inflammatory activity of PUR1800
(RV1162) in primary cells cultured from healthy subjects and COPD
patients," said David Hava, PhD,
chief scientific officer of Pulmatrix. "These preclinical
studies, together with our recently completed IND-enabling
non-clinical safety inhalation studies, continue to support the
development of PUR1800 as a therapy to treat acute exacerbations of
COPD. We look forward to advancing PUR1800 to the
clinic."
About Pulmatrix
Pulmatrix is a
clinical stage biopharmaceutical company developing innovative
inhaled therapies to address serious pulmonary disease using its
patented iSPERSE™ technology. The Company's proprietary product
pipeline is focused on advancing treatments for serious lung
diseases, including Pulmazole, an inhaled anti-fungal for patients
with allergic bronchopulmonary aspergillosis ("ABPA"), and PUR1800,
a narrow spectrum kinase inhibitor for patients with obstructive
lung diseases including asthma and chronic obstructive pulmonary
disease ("COPD"). In addition, Pulmatrix has partnered with Vectura
Group plc to develop Pulmatrix's drug candidate, PUR0200, for COPD
for the U.S. market. Pulmatrix's product candidates are based on
iSPERSE™, its proprietary engineered dry powder delivery platform,
which seeks to improve therapeutic delivery to the lungs by
maximizing local concentrations and reducing systemic side effects
to improve patient outcomes.
FORWARD-LOOKING STATEMENTS
Certain statements in this
press release that are forward-looking and not statements of
historical fact are forward-looking statements within the meaning
of the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. The Company cautions that such statements
involve risks and uncertainties that may materially affect the
Company's results of operations. Such forward-looking statements
are based on the beliefs of management as well as assumptions made
by and information currently available to management. Actual
results could differ materially from those contemplated by the
forward-looking statements as a result of certain factors,
including but not limited to the ability to establish that
potential products are efficacious or safe in preclinical or
clinical trials; the ability to establish or maintain
collaborations on the development of therapeutic candidates; the
ability to obtain appropriate or necessary governmental approvals
to market potential products; the ability to obtain future funding
for developmental products and working capital and to obtain such
funding on commercially reasonable terms; the Company's ability to
manufacture product candidates on a commercial scale or in
collaborations with third parties; changes in the size and nature
of competitors; the ability to retain key executives and
scientists; and the ability to secure and enforce legal rights
related to the Company's products, including patent protection. A
discussion of these and other factors, including risks and
uncertainties with respect to the Company, is set forth in the
Company's filings with the Securities and Exchange Commission,
including its annual report on Form 10-K filed by the Company with
the Securities and Exchange Commission on March 13, 2018, as may be supplemented or amended
by the Company's Quarterly Reports on Form 10-Q. The Company
disclaims any intention or obligation to revise any forward-looking
statements, whether as a result of new information, future events
or otherwise, except as required by law.
Investor
Contact
|
|
Robert Clarke,
CEO
|
William Duke,
CFO
|
(781)
357-2333
|
(781)
357-2333
|
rclarke@pulmatrix.com
|
wduke@pulmatrix.com
|
View original content to download
multimedia:http://www.prnewswire.com/news-releases/pulmatrix-to-present-pre-clinical-data-on-pur1800-rv1162-at-the-european-respiratory-society-international-congress-300713630.html
SOURCE Pulmatrix, Inc.